secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001999371-24-004298
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q4 2023 net loss $27.3M; cash down to $24.9M; Tonmya NDA on track for H2 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $27.3M ($0.86/share) vs $34.1M ($3.42) in Q4 2022; full year net product revenue $7.8M.
- Cash and equivalents $24.9M at Dec 31, 2023 vs $120.2M at Dec 31, 2022; net cash used in operations $102M.
- Pre-NDA meeting with FDA for Tonmya (cyclobenzaprine SL) for fibromyalgia scheduled Q2 2024; NDA submission planned H2 2024.
- Raised $4.4M in registered direct offering on March 28, 2024; also $11M term loan executed Dec 2023.
- Completed transition to fully integrated pharma with marketed migraine products Zembrace and Tosymra.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/0001999371-24-004298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/tnxp_8k-040124.htm
  HTML page:      https://secwatch.observer/filing/0001999371-24-004298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer